Health technology assessment for the acute and preventive treatment of migraine: A position statement of the International Headache Society.

Hans Christoph Diener,Gisela Terwindt,Daniel A Ollendorf,Richard B Lipton,Isabelle Durand-Zaleski,Patricia Pozo-Rosich,Cristina Tassorelli,Michel Lantéri-Minet,Tobias Kurth,Messoud Ashina

doi:10.1177/0333102421989247

Abstract

The Clinical Trials Subcommittee of the International Headache Society presents the first Health Technology Assessment for the Acute Treatment of Migraine Attacks and Prevention of Migraine. Health technology assessments are systematic evaluations of the properties, effects, and consequences of healthcare technologies; this position statement is designed to inform decision makers about access to and reimbursement for medications and devices for the acute and preventive treatment of migraine. This position statement extends beyond the already available guidelines on randomized controlled trials for migraine to incorporate real-world evidence and a synthetic approach for considering multiple data sources and modelling methods when assessing the value of migraine treatments.

Highlights

According to the World Health Organization, a health technology is the application of scientific knowledge, which can take the form of pharmaceuticals, medical devices, and procedures, as well as management, communication, and information systems, to solving health problems [1]
To facilitate the development of an evidence base for migraine that clarifies the effects of new technologies for acute and preventive treatments for regulators and payers who rely on Health technology assessment (HTA) for decision making, the Clinical Trials Subcommittee of the International Headache Society presents the first Health Technology Assessment for the Acute Treatment of Migraine Attacks and Prevention of Migraine: A Position Statement of the International Headache Society
Comparisons involving new technologies for the acute and preventive treatment of migraine require that HTAs consider multiple dimensions, but in patients with migraine it is especially important that assessments incorporate individual and societal needs

Summary

Introduction

According to the World Health Organization, a health technology is the application of scientific knowledge, which can take the form of pharmaceuticals, medical devices, and procedures, as well as management, communication, and information systems, to solving health problems [1]. Health technology assessments (HTAs) are characterized as systematic evaluations of the properties, effects, and direct and indirect consequences of a healthcare technology that are intended to inform decision makers [1]. HTAs identify and analyse the clinical, patient-related, organizational, economic, ethical, and legal issues associated with new health technologies to facilitate the evidence-based allocation of healthcare resources [2]. To facilitate the development of an evidence base for migraine that clarifies the effects of new technologies for acute and preventive treatments for regulators and payers who rely on HTAs for decision making, the Clinical Trials Subcommittee of the International Headache Society presents the first Health Technology Assessment for the Acute Treatment of Migraine Attacks and Prevention of Migraine: A Position Statement of the International Headache Society

Objectives

Findings

Declaration of conflicting interests